One-stage transurethral resection of the urinary bladder and the prostate in patients with superficial cancer of the urinary bladder combined with benign prostatic hyperplasia
- Authors: Karaguzhin SG1, Merinov DS1, Martov AG1
-
Affiliations:
- Issue: No 5 (2005)
- Pages: 17-21
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/276599
- ID: 276599
Cite item
Full Text
Abstract
Combination of urinary bladder cancer (UBC) with benign prostatic hyperplasia (BPH) is a prognostically unfavourable factor. To
assess clinical efficacy of one-stage transurethral resection of UBC and BPH in combination with adjuvant immunotherapy, we examined 181 patients with UBC stage Tis, Ta-Tl and BTH. All the patients have undergone one- and two-stage endoscopic operations. TUR of the urinary bladder and the prostate was made in 87 patients. Stage-by-stage TUR of the urinary bladder and TUR of the prostate were made in 94 controls. We conducted postoperative immunotherapy with BCG vaccine (imuron) as an adjuvant therapy in 114 (63%) patients. Postoperative UBC recurrence occurred in 124 (68.5%) patients: 49 (56.3%) patients of the study group and 75 (79.7%) controls (p < 0.05). Reoperation (TUR of the urinary bladder) was performed in all cases of UBC recurrence. Five-year survival in the study group was 71% and 68.0% survived in the control group (p > 0.05). The conclusion is made that in combination of superficial UBC with BPH indications appear for TUR of the urinary bladder and TUR of the prostate with adjuvant immunotherapy. Early elimination of infravesical obstruction lowers UBC recurrence rate and improves the patients' quality of life.
assess clinical efficacy of one-stage transurethral resection of UBC and BPH in combination with adjuvant immunotherapy, we examined 181 patients with UBC stage Tis, Ta-Tl and BTH. All the patients have undergone one- and two-stage endoscopic operations. TUR of the urinary bladder and the prostate was made in 87 patients. Stage-by-stage TUR of the urinary bladder and TUR of the prostate were made in 94 controls. We conducted postoperative immunotherapy with BCG vaccine (imuron) as an adjuvant therapy in 114 (63%) patients. Postoperative UBC recurrence occurred in 124 (68.5%) patients: 49 (56.3%) patients of the study group and 75 (79.7%) controls (p < 0.05). Reoperation (TUR of the urinary bladder) was performed in all cases of UBC recurrence. Five-year survival in the study group was 71% and 68.0% survived in the control group (p > 0.05). The conclusion is made that in combination of superficial UBC with BPH indications appear for TUR of the urinary bladder and TUR of the prostate with adjuvant immunotherapy. Early elimination of infravesical obstruction lowers UBC recurrence rate and improves the patients' quality of life.
References
- Лопаткин Н. А. Руководство по урологии. М.; 1998. 258.
- Матвеев Б. П., Фигурин К. М., Корякин О. Б. Рак мочевого пузыря. М.; 2001. 9-10.
- Мартов А. Г., Гущин Б. Л. и др. Эндоскопическое лечение рака мочевого пузыря с доброкачественной гиперплазией предстательной железы. В кн.: Рак мочевого пузыря: Материалы Межрегиональной конф. Воронеж; 2002.
- Переверзев А. С., Петров С. Б. Опухоли мочевого пузыря. Харьков; 2002. 8-10. 246-255.
- Аль-Шукри С. X., Корнеев И. А., Козлов В. В. Доброкачественная гиперплазия простаты - прогностический неблагоприятный фактор у больных раком мочевого пузыря. В кн.: Тезисы докладов 2-го съезда Ассоциации урологов Дона. Ростов н/Д; 1996. 9-10.
- Malmstrom P. U., Thorn M., Lindblad P. et al. Increasing survival of patients with urinarv bladder cancer. A nation-wide study in Sweeden 1960-1986. Eur. J. Cancer 1993; 29АПЗ): 1868-1872.
- Mommsen S., Sell A. Prostatic hypertrophy and venereal disease as posiible risk factors in the development of bladder cancer. Urol. Res. 1983; 11(2): 49-52.
- Яненко Э. К., Громов Ю. В. Диагностика и лечение больных раком мочевого пузыря при сочетании с аденомой предстательной железы. В кн.: Тезисы докладов 8-го Пленума Всесоюзного науч. о-ва урологов. Вильнюс: 1988. 147-149.
- Tsivian A., Shtricker A., Sidi A. A. Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver? J. Urol. (Baltimore) 2003; 170(6, pt 1): 2241-2243.
- Андреев И. И., Черныш П. Б., Козин Ю. И. Особенности лечения больных при сочетании рака мочевого пузыря с аденомой простаты. В кн.: Опухоли почек и мочевых путей: Материалы научно-практической конф. урологов. Харьков; 1994. 137-138.
- Wigura A. Coexistence of prostatic adenoma and bladder neoplasm. Pol. Przegl. Chir. 1977: 49(6a): ~49- 751.
- Rammou-Kinia R., Anagnostopoulou I. Detection of bladder tumor by urine cytology in cases of prostatic hypertrophy. Diagn. Cytopathol. 1996; 15(5): 409-411.
- Vicente J., Chechile C., Pons R., Mendez G. Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate. Eur. Urol. 1988; 15(1-2): 40-42.
- Greene L. F., Yalowitz P. A. The advisability of concomitant transurethral excision of vesical neoplasm and prostatic hyperplasia. J. Urol. (Baltimore) 1972; 107(3): 445-448.
Supplementary files
